BRIEF—Flow Pharma looks east to develop cancer vaccines

San Francisco’s Flow Pharma has formed a joint venture in China, named Hefei Sageland Biotechnology, together with Button Capital, a cross-border investment and consulting company based in China.

Lu Wang, general manager of the new JV, said the firm would “test our FlowVax vaccines directed against neoantigens expressed on cancer cells.”

“We are working with the best physicians and scientists in the field. Our newly formed JV will enable us to contract with, and help fund, manufacturing and testing activities needed for clinical trials in China,'' he added.